Moreover, EML4‐ALK expressing cells with various ALK mutations including L1196M show higher susceptibility to other ALK inhibitors such as ceritinib, brigatinib and lorlatinib, which are off‐label for ALK+ALCL, than alectinib[10]. Here, EML4 is linked to anaplastic large cell lymphoma.